The international conference will present the most current and innovative immunotherapy research, with a focus on the pathological functions of myeloid-derived suppressor cells, dendritic cells, macrophages, and neutrophils.

6 sessions over the 4 days will examine the basic and translational aspects of regulatory myeloid cells in cancer and other pathological conditions.

**Keynote SPEAKER:**
**Robert A. Weinberg, PhD**
MIT and Whitehead Institute for Biomedical Research

Register online at: www.myeloidsuppressors.com

---

**Speakers & SESSIONS**

**Session 1, June 16th** – Origin and natural history of regulatory myeloid cells
*Dmitry I. Gabrilovich, The Wistar Institute; Ming O. Li, Memorial Sloan Kettering Cancer Institute; Miriam Merad, Icahn School of Medicine at Mount Sinai; Suzanne Ostrand-Rosenberg, University of Maryland, and Mikael J. Pittet, Harvard University*

**Session 2, June 16-17th** – Mechanisms that control accumulation and function of regulatory myeloid cells
*Scott Abrams, Roswell Park Cancer Institute; Vincenzo Bronte, University of Verona; José R. Conejo-Garcia, The Wistar Institute; Juan R. Cubillos-Ruiz, Weill Cornell Medical College; Tim F. Greten, Center for Cancer Research, NCI; Augusto Ochoa, Louisiana State University; Antonio Sica, Humanitas Clinical and Research Center, and Jie Zhou, Sun Yet-Sen University*

**Session 3, June 17th** – Contribution of regulatory myeloid cells to immune responses
*Michal Baniyash, The Hebrew University of Jerusalem; Evgeniy B. Eruslanov, University of Pennsylvania; Zvi G. Fridlender, Hadassah University Medical Center; Luis J. Montaner, The Wistar Institute; Peter J. Murray, St. Jude Children's Research Hospital, and Viktor Umansky, German Cancer Research Center*

**Session 4, June 18th** – Contribution of regulatory myeloid cells to pathobiology of cancer
*Mario Colombo, Italian National Cancer Institute; Alberto Mantovani, Humanitas Clinical and Research Center; Jeffrey W. Pollard, The University of Edinburgh; Paul Rodriguez, Louisiana State University; Jo van Ginderachter, Vrije Universiteit Brussels; Sheng Wei, H. Lee Moffit Cancer Center, and Weiping Zou, University of Michigan*

**Session 5, June 18th** – Clinical significance of regulatory myeloid cells
*Sven Brandau, University Hospital Essen; Graham Pawelec, University of Tübingen, and Jeffrey S. Weber, NYU Langone Medical Center*

**Session 6, June 19th** – Therapeutic targeting of myeloid cells
*Ron N. Apte, Ben-Gurion University of the Negev; Bruce R. Blazar, University of Minnesota; Ivan M. Borello, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center; Shu-Hsia Chen, Mount Sinai School of Medicine; David G. DeNardo, Washington University; Rolf Kiessling, Karolinska Institutet; Marcin Kortylewski, City of Hope Cancer Center; Vinit Kumar, The Wistar Institute; David H. Munn, Georgia Regents University, and Michael Shurin, University of Pittsburgh*